27 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Apr 2027
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2033 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends Apr 2027 · High confidence
Also notable
Ends Nov 2033 · High confidence
Also notable
Ends Jul 2034 · High confidence
Also notable
Ends Jun 2032 · High confidence
Also notable
Ends Jun 2030 · High confidence
Also notable
Ends Oct 2037 · High confidence
Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof
US 10,125,171
Cited by 51 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Methods of Treating Chronic Disorders with Complement Inhibitors
US 10,039,802
Cited by 82 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Methods of Treating Age-Related Macular Degeneration by Compstatin and Analogs Thereof
US 8,168,584
Cited by 81 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Related Compositions and Methods
US 10,035,822
Cited by 40 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Cell-Penetrating Compstatin Analogs and Uses Thereof
US 10,308,687
Cited by 39 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2034.
Compstatin Analogs for Treatment of Neuropathic Pain
US 9,421,240
Cited by 54 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Local Complement Inhibition for Treatment of Complement-Mediated Disorders
US 8,580,735
The most cited patent in this portfolio, cited by 89 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2030.
Combination Therapy for C3 Inhibition
US 11,338,013
Cited by 17 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof (US 11,661,441) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Dec 4, 2026The maintenance fee for Cell-Penetrating Compstatin Analogs and Uses Thereof (US 10,308,687) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Methods of Treating Chronic Disorders with Complement Inhibitors (US 11,712,460) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Dosing Regimens and Related Compositions and Methods (US 11,844,841) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Dosing Regimens (US 11,903,994) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Oct 25 US 9,056,076 A method of treating age-related macular degeneration comprising administering a compstatin analog · term ended
- Oct 6 US 10,407,466 Methods of Selecting Compstatin Mimetics · term ended
What they patent
The largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,584 | Methods of Treating Age-Related Macular Degeneration by Compstatin and Analogs Thereof In force · High confidence | In force | High confidence | |
| US 8,580,735 | Local Complement Inhibition for Treatment of Complement-Mediated Disorders In force · High confidence | In force | High confidence | |
| US 10,696,718 | Compstatin Analogs for Treatment of Neuropathic Pain In force · High confidence | In force | High confidence | |
| US 11,001,610 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,421,240 | Compstatin Analogs for Treatment of Neuropathic Pain In force · High confidence | In force | High confidence | |
| US 11,013,782 | Methods of Treating Chronic Disorders with Complement Inhibitors In force · High confidence | In force | High confidence | |
| US 11,712,460 | Methods of Treating Chronic Disorders with Complement Inhibitors In force · High confidence | In force | High confidence | |
| US 11,661,441 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,125,171 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,291,407 | Detection of High Risk Drusen In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 2 patents in force now held by others · 4 patents ended · 23 applications pending · 36 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.